Reuters logo
BRIEF-Staidson Beijing Biopharmaceuticals sees FY 2017 H1 net profit to increase by 10 pct to 30 pct
July 10, 2017 / 7:57 AM / in 3 months

BRIEF-Staidson Beijing Biopharmaceuticals sees FY 2017 H1 net profit to increase by 10 pct to 30 pct

July 10(Reuters) - Staidson Beijing Biopharmaceuticals Co Ltd :

* Says net profit for FY 2017 H1 to increase by 10 percent to 30 percent, or to be 130.2 million yuan to 153.9 million yuan, compared to net profit of FY 2016 H1 (118.4 million yuan)

* Says stable growth of performance as main reason for the forecast

Source text in Chinese: goo.gl/HwKUu4

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below